Unknown

Who we are

  • April 5, 2022
    A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
  • April 5, 2022
    A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
  • April 5, 2022
    PIPAC for the Treatment of Colorectal Peritoneal Metastases
  • April 5, 2022
    Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
  • April 5, 2022
    A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
  • April 5, 2022
    A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
  • April 5, 2022
    A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
  • April 5, 2022
    The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
  • April 5, 2022
    Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
  • April 5, 2022
    Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer